The CEO of Novo Nordisk was questioned about the high cost in the U.S. of Wegovy and Ozempic, the wildly popular diabetes and weight-loss drugs. Lars Jorgensen said pharmacy benefit managers are mostly to blame. NBC News' Stephanie Gosk reports.
The CEO of Novo Nordisk was questioned about the high cost in the U.S. of Wegovy and Ozempic, the wildly popular diabetes and weight-loss drugs.
Lars Jorgensen said pharmacy benefit managers are mostly to blame. NBC News' Stephanie Gosk reports. Sept.
24, 2024.
